MedPath

Effects of Cigar Flavors on Measures of Abuse Liability Among Young Adults

Not Applicable
Completed
Conditions
Tobacco Products
Interventions
Other: Tobacco product administration and assessment
Registration Number
NCT02937051
Lead Sponsor
Virginia Commonwealth University
Brief Summary

This study involves 25 current young adult combustible tobacco cigarette (CTC) smokers who will complete 5 Latin square ordered, within-subject, laboratory conditions that differ by the tobacco product smoked:

1. own-brand CTC (positive control),

2. original-flavored Black \& Mild (B\&M) cigar,

3. apple-flavored B\&M cigar,

4. cream-flavored B\&M cigar, and

5. wine-flavored B\&M cigar.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
25
Inclusion Criteria
  • To be included, participants must be healthy, as determined by self-report and heart rate/blood pressure (HR/BP) check, between the ages of 18-25, and willing to provide informed consent.
  • They must agree to attend the lab and abstain from tobacco/nicotine as required, to use the designated products, and to follow the study protocol.
  • Participants must also be regular CTC smokers (≥5 cigarettes/day for past 3 months) naïve to cigar products (smoked no more than 10 cigar products of any type in lifetime) who can provide a semi-quantitative urine cotinine result of ≥3 at screening (NicAlert test).
Read More
Exclusion Criteria
  • Individuals with a self-reported history of chronic diseases or psychiatric conditions will be excluded.
  • Other exclusion criteria are: history of or active cardiovascular disease, current oral health problems or injuries, low/high BP, seizures, regular prescription medication use (other than vitamins or birth control), and past month use of cocaine, opioids, benzodiazepines, and methamphetamine (self-report).
  • Individuals who report using marijuana or alcohol >20 days in the past 30 or interest in quitting CTC use within the next 30 days will also be excluded.
  • Women will be excluded if they are breast-feeding or test positive for pregnancy (by urinalysis) at screening.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Own Brand Cigarette ConditionTobacco product administration and assessment-
Apple-flavor Black&Mild cigarTobacco product administration and assessment-
Original-flavor Black&Mild cigarTobacco product administration and assessment-
Cream-flavor Black&Mild cigarTobacco product administration and assessment-
Wine-flavor Black&Mild cigarTobacco product administration and assessment-
Primary Outcome Measures
NameTimeMethod
Change in saliva nicotine concentrationSaliva will be collected at baseline before the first product administration, at 10 min following each product administration, and 55 min following the first product administration (baseline for the second product administration).

Each participant will attend 5 study sessions, each study session will include two bouts of product administration. Product administration will consist of 10 puffs with a 30-second interpuff interval (IPI; puff number and IPI will be directed and monitored by staff).

Change in Tobacco Abstinence Symptoms and Drug Effects subjective abuse liabilitySubjective measures of abuse liability will be collected at baseline before the first product administration, 5, 15, 30, and 45 min following each bout.

Each participant will attend 5 study sessions, each study session will include two bouts of product administration. Product administration will consist of 10 puffs with a 30-second interpuff interval (IPI; puff number and IPI will be directed and monitored by staff).

Change in breakpoint from two behavioral choice tasks (Cigarette Purchase Task, Multiple Choice Procedure)A behavioral choice task (cigarette purchase cask) will be completed at baseline before the first product administration, 5, 15, 30, and 45 min following each bout. 45 min after the second bout, the multiple choice procedure will be administered.

Each participant will attend 5 study sessions, each study session will include two bouts of product administration. Product administration will consist of 10 puffs with a 30-second interpuff interval (IPI; puff number and IPI will be directed and monitored by staff).

Change in Addiction Research Center Inventory subjective abuse liabilitySubjective measures of abuse liability will be collected at baseline before the first product administration, 5, 15, 30, and 45 min following each bout.

Each participant will attend 5 study sessions, each study session will include two bouts of product administration. Product administration will consist of 10 puffs with a 30-second interpuff interval (IPI; puff number and IPI will be directed and monitored by staff).

Change in Direct Effects of Nicotine and Tobacco Scale subjective abuse liabilitySubjective measures of abuse liability will be collected at baseline before the first product administration, 5, 15, 30, and 45 min following each bout.

Each participant will attend 5 study sessions, each study session will include two bouts of product administration. Product administration will consist of 10 puffs with a 30-second interpuff interval (IPI; puff number and IPI will be directed and monitored by staff).

Secondary Outcome Measures
NameTimeMethod
Expired air carbon monoxideExpired air carbon monoxide measurement will occur at baseline before the first product administration, 15 minutes following each bout, 55 min following the first product administration (baseline for the second product administration).

Each participant will attend 5 study sessions, each study session will include two bouts of product administration. Product administration will consist of 10 puffs with a 30-second interpuff interval (IPI; puff number and IPI will be directed and monitored by staff).

Puff Duration (seconds)Puff Duration will be measured in seconds for each puff during product administration (10 puffs with a 30-second interpuff interval directed and monitored by staff)

The instrument senses flow-induced pressure drop across an orifice that is incorporated into the mouthpiece. Each participant will attend 5 study sessions, each study session will include two bouts of product administration. Puff Volume and Puff Duration will be used to calculate measures of Puff Flow Rate (Puff Volume/Puff Duration) and Total Puff Volume (Puff Volume per puff x 10 puffs).

Heart rateHeart rate will be recorded at one second intervals from session onset (minute zero of session) through minute 155 of the session (end of session).

Each participant will attend 5 study sessions, each study session will include two bouts of product administration.Product administration will consist of 10 puffs with a 30-second interpuff interval (IPI; puff number and IPI will be directed and monitored by staff).

Blood pressureBlood pressure will be recorded at 5 minute intervals from from session onset (minute zero of session) through minute 155 of the session (end of session).

Each participant will attend 5 study sessions, each study session will include two bouts of product administration.Product administration will consist of 10 puffs with a 30-second interpuff interval (IPI; puff number and IPI will be directed and monitored by staff).

Puff Volume (ml)Puff Volume will be measured in seconds for each puff during product administration (10 puffs with a 30-second interpuff interval directed and monitored by staff)

The instrument senses flow-induced pressure drop across an orifice that is incorporated into the mouthpiece. Each participant will attend 5 study sessions, each study session will include two bouts of product administration. Puff Volume and Puff Duration will be used to calculate measures of Puff Flow Rate (Puff Volume/Puff Duration) and Total Puff Volume (Puff Volume per puff x 10 puffs).

Trial Locations

Locations (1)

VCU Behavioral Health Research Laboratory

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath